Supplementary materials: Cost-utility of real-time continuous glucose monitoring versus self-monitoring of bloodglucose in people with insulin-treated Type II diabetes in France

<p dir="ltr"><b>These are peer-reviewed supplementary tables for the article '</b><b>Cost-utility of real-time continuous glucose </b><b>monitoring versus self-monitoring of blood </b><b>glucose in people with insulin-treated Type </b><b>II diabetes in France</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><p dir="ltr"><br></p><ul><li><b>Supplemental Table S1</b><b>:</b> Utility and disutility values for events/states.</li><li><b>Supplemental Table S2: </b>Costs per diabetes complication or event.</li><li><b>Supplemental Table S3: </b>Annual treatment and device costs.</li><li><b>Supplemental Table S4: </b>Projected diabetes complications for rt-CGM versus SMBG</li><li><b>References</b><b>:</b> References for online-only supplementary material.</li></ul><p dir="ltr"><b>Aim:</b> Clinical trials and real-world data for Type II diabetes both show that glycated hemoglobin (HbA1c)</p><p dir="ltr">levels and hypoglycemia occurrence can be reduced by real-time continuous glucose monitoring (rt-CGM)</p><p dir="ltr">versus self-monitoring of blood glucose (SMBG). The present cost-utility study investigated the long-term</p><p dir="ltr">health economic outcomes associated with using rt-CGM versus SMBG in people with insulin-treated Type</p><p dir="ltr">II diabetes in France. <b>Materials & methods:</b> Effectiveness data were obtained from a real-world study,</p><p dir="ltr">which showed rt-CGM reduced HbA1c by 0.56% (6.1 mmol/mol) versus sustained SMBG. Analyses were</p><p dir="ltr">conducted using the IQVIA Core Diabetes Model. A French payer perspective was adopted over a lifetime</p><p dir="ltr">horizon for a cohort aged 64.5 years with baseline HbA1c of 8.3% (67 mmol/mol). A willingness-to-pay</p><p dir="ltr">threshold of €147,093 was used, and future costs and outcomes were discounted at 4% annually. <b>Results:</b></p><p dir="ltr">The analysis projected quality-adjusted life expectancy was 8.50 quality-adjusted life years (QALYs) for rt-</p><p dir="ltr">CGM versus 8.03 QALYs for SMBG (difference: 0.47 QALYs), while total mean lifetime costs were €93,978</p><p dir="ltr">for rt-CGM versus €82,834 for SMBG (difference: €11,144). This yielded an incremental cost-utility ratio</p><p dir="ltr">(ICUR) of €23,772 per QALY gained for rt-CGM versus SMBG. Results were particularly sensitive to changes</p><p dir="ltr">in the treatment effect (i.e., change in HbA1c), annual price and quality of life benefit associated with</p><p dir="ltr">rt-CGM, SMBG frequency, baseline patient age and complication costs. <b>Conclusion:</b> The use of rt-CGM is</p><p dir="ltr">likely to be cost-effective versus SMBG for people with insulin-treated Type II diabetes in France.</p>